Additionally, in the ongoing phase III BEACON CRC trial, 30 CRC patients with BRAF V600E mutation received a combination of the B-RAF inhibitor (encorafenib), with an inhibitor of its downstream target MEK (binimetinib), in addition to cetuximab. This evidence concerns the gene MAP2K7 and colorectal carcinoma.